What are the treatment options for Herpes Simplex Virus (HSV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testing and Treatment of Herpes Simplex Virus (HSV)

For HSV infections, antiviral medications including valacyclovir, famciclovir, and acyclovir are the cornerstone of treatment, with specific regimens based on whether the infection is a first episode, recurrent episode, or requires suppressive therapy. 1

Diagnostic Testing

  • Viral culture: Collect specimen from active lesions within 48 hours of appearance
  • PCR testing: More sensitive than viral culture, especially for CSF or lesions that are healing
  • Serologic testing: Can differentiate between HSV-1 and HSV-2 antibodies to confirm past infection
  • Tzanck smear: Rapid but less sensitive test that can detect multinucleated giant cells

Treatment Options

First Episode Treatment

Medication Dosage
Valacyclovir 1 gram twice daily for 7-10 days
Famciclovir 250 mg three times daily for 7-10 days
Acyclovir 400 mg three times daily for 7-10 days

Recurrent Episode Treatment

Medication Dosage
Valacyclovir 500 mg twice daily for 5-10 days or 1 gram twice daily for 1 day (for oral herpes)
Famciclovir 125 mg twice daily for 5 days or 1000 mg twice daily for 1 day (for genital herpes)
Acyclovir 400 mg three times daily for 5-10 days

Suppressive Therapy

For patients with ≥6 recurrences per year or those who desire suppression:

Medication Dosage
Valacyclovir 500-1000 mg once daily
Famciclovir 250 mg twice daily
Acyclovir 400 mg twice daily

Special Populations

HIV-Infected Patients

  • Require longer courses of therapy and closer monitoring 1
  • For suppressive therapy: Valacyclovir 500 mg twice daily

Pregnant Patients

  • Acyclovir is preferred due to established safety profile

Immunocompromised Patients

  • Require longer treatment duration and closer monitoring
  • Note: Famciclovir has not been established for immunocompromised patients other than HIV-infected patients with recurrent orolabial or genital herpes 2

Treatment Selection Considerations

  • Convenience: Valacyclovir and famciclovir offer less frequent dosing (1-2 times daily) compared to acyclovir (3-5 times daily) 1, 3
  • Bioavailability: Valacyclovir provides better oral bioavailability than acyclovir 3
  • Efficacy: All three medications have comparable efficacy when used at appropriate doses 4, 5

Management of Resistant HSV

For acyclovir-resistant HSV (primarily in immunocompromised patients):

  1. Increase oral acyclovir to 800 mg five times daily
  2. If no response after 5-7 days, consider:
    • Topical trifluridine for accessible lesions
    • Intravenous foscarnet (40 mg/kg three times daily or 60 mg/kg twice daily) for 10 days 6

Prevention of Transmission

  • Avoid direct contact with active lesions
  • Use latex condoms during sexual activity
  • Consider daily suppressive antiviral therapy for those with frequent recurrences
  • Practice good hygiene, including regular handwashing 1

Pain Management

For pain associated with HSV infections:

  • Mild pain: Acetaminophen or NSAIDs
  • Moderate to severe pain: Consider gabapentin, pregabalin, or tricyclic antidepressants 1

Follow-up Recommendations

Patients should be re-examined 3-7 days after treatment initiation to:

  • Assess treatment response
  • Monitor for complete resolution of lesions
  • Evaluate for signs of complications
  • Ensure appropriate specialist referral if needed (e.g., ophthalmology for ocular involvement) 1

Common Pitfalls

  • Delayed treatment: Antiviral therapy is most effective when started within 72 hours of symptom onset
  • Inadequate dosing: Ensure proper dosage adjustments for patients with renal impairment 1, 2
  • Failure to recognize resistance: Consider resistance in immunocompromised patients with poor response to standard therapy
  • Insufficient patient education: Patients should understand the chronic nature of HSV and strategies to prevent transmission

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.